Tempus AI Research and Development Expenses 2023-2025 | TEM
Tempus AI annual/quarterly research and development expenses history and growth rate from 2023 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Tempus AI research and development expenses for the quarter ending June 30, 2025 were $0.076B, a 47.85% decline year-over-year.
- Tempus AI research and development expenses for the twelve months ending June 30, 2025 were $0.265B, a 1.98% decline year-over-year.
- Tempus AI annual research and development expenses for 2024 were $0.317B, a 70.81% increase from 2023.
- Tempus AI annual research and development expenses for 2023 were $0.185B, a 14.33% increase from 2022.
- Tempus AI annual research and development expenses for 2022 were $0.162B, a 0% decline from .
| Tempus AI Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2024 | $317 |
| 2023 | $185 |
| 2022 | $162 |
| Tempus AI Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025-06-30 | $76 |
| 2025-03-31 | $69 |
| 2024-12-31 | $61 |
| 2024-09-30 | $58 |
| 2024-06-30 | $146 |
| 2024-03-31 | $51 |
| 2023-12-31 | $25 |
| 2023-09-30 | $47 |
| 2023-06-30 | $46 |
| 2023-03-31 | $44 |
| 2022-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $13.629B | $0.693B |
| Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $46.099B | 58.65 |
| Doximity (DOCS) | United States | $12.349B | 54.94 |
| Hims & Hers Health (HIMS) | United States | $10.193B | 83.52 |
| IRhythm Technologies (IRTC) | United States | $5.074B | 0.00 |
| Hinge Health (HNGE) | United States | $4.605B | 0.00 |
| Privia Health (PRVA) | United States | $2.623B | 194.27 |
| Inspire Medical Systems (INSP) | United States | $2.613B | 38.41 |
| Heartflow (HTFL) | $2.433B | 0.00 | |
| Phreesia (PHR) | United States | $1.732B | 0.00 |
| Enovis (ENOV) | United States | $1.689B | 8.93 |
| 10x Genomics (TXG) | United States | $1.676B | 0.00 |
| Schrodinger (SDGR) | United States | $1.476B | 0.00 |
| Omnicell (OMCL) | United States | $1.452B | 27.97 |
| Azenta (AZTA) | United States | $1.394B | 60.84 |
| Clover Health Investments (CLOV) | United States | $1.338B | 0.00 |
| Claritev (CTEV) | United States | $1.189B | 0.00 |
| Evolent Health (EVH) | United States | $1.059B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.659B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.630B | 0.00 |
| Veradigm (MDRX) | United States | $0.503B | 0.00 |
| Standard BioTools (LAB) | United States | $0.482B | 0.00 |
| Talkspace (TALK) | United States | $0.435B | 130.00 |
| Butterfly Network (BFLY) | United States | $0.363B | 0.00 |
| Carlsmed (CARL) | $0.349B | 0.00 | |
| TruBridge (TBRG) | United States | $0.290B | 50.90 |
| Outset Medical (OM) | United States | $0.243B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.236B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.224B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.211B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.195B | 0.00 |
| CapsoVision (CV) | United States | $0.187B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.141B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.125B | 0.00 |
| American Well (AMWL) | United States | $0.117B | 0.00 |
| CareCloud (CCLD) | United States | $0.115B | 5.23 |
| EUDA Health Holdings (EUDA) | Singapore | $0.098B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.076B | 0.00 |
| Pulmonx (LUNG) | United States | $0.065B | 0.00 |
| 111 (YI) | China | $0.062B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.050B | 0.00 |
| HeartBeam (BEAT) | United States | $0.041B | 0.00 |
| Precipio (PRPO) | United States | $0.024B | 0.00 |
| Zhongchao (ZCMD) | China | $0.023B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.019B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.013B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.009B | 0.00 |
| HeartSciences (HSCS) | United States | $0.009B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.007B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.005B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.004B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| PROFUSA (PFSA) | United States | $0.003B | 0.00 |